Global BioClinical

Global BioClinical (GBC) are Boudicca DX are Partners!

GBC Partners with Boudicca DX to become a one stop global shop for STRATEGY and EX*****ON for Medical Device 🩻 & In Vitro Diagnostic 🧬 Companies saving them ⏰ & 💰!

See press release here:

boudiccadx.com

Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF), results in tracing it to a group of distinct but mysterious Europeans who lived about 5,000 years ago. CF is the most common, potentially lethal, inherited disease among Caucasians – about one in 40 carry the so-called F508del mutation. [ 2,171 more words ]

Discovering the Ancient Origin of Cystic Fibrosis, The Most Common Genetic Disease in Caucasians Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF), results in tracing it to a group of distinct but mysterious Euro…

Seattle’s Integrated Diagnostics Acquired by Lung Cancer Technology Company Biodesix Colorado-based Biodesix, a company that creates technology around lung cancer, announced that it has acquired Seattle’s Integrated Diagnostics for an undisclosed sum. Integrated Diagnostics, also known as Indi, develops a test that can rule out patients who do not have lung cancer using a simple blood draw, a less invasive and more cost-effective option than the traditional lung biopsy. [ 190 more words ]

Seattle’s INDI Acquired by Lung Cancer Tech Company Biodesix Seattle’s Integrated Diagnostics Acquired by Lung Cancer Technology Company Biodesix Colorado-based Biodesix, a company that creates technology around lung cancer, announced that it has acquired Se…

- Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe - Prospective U.S. trial for FDA submission to be initiated in 2019 - Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), July 2, 2018 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced it's plan to CE Mark mSEPT9 blood test by year-end 2018 to aid in detecting liver cancer among patients with cirrhosis. [ 389 more words ]

Epigenomics AG: Liquid Biopsy Test for Liver Cancer Detection to obtain CE Mark – Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe – Prospective U.S. trial for FDA submission to be initiated in 2…